‘Sixth largest clinical trial’ supports probiotics for digestive health

By Stephen Daniells contact

- Last updated on GMT

© Getty Images / Nastco
© Getty Images / Nastco

Related tags: Probiotics, Ibs, Digestive health

Supplementation with select probiotic strains may improve symptoms associated with irritable bowel syndrome (IBS) and boost quality of life, says a large clinical trial from UAS Labs.

The study, which is said to be the sixth largest probiotic-digestive health clinical trial, used either Lactobacillus acidophilus​ DDS-1 or Bifidobacterium animalis​ subsp. lactis​ UABla-12 for six weeks. Over 300 people participated in the study.

Data published in Nutrients​ indicated that both probiotic strains led to significant improvements in the IBS Symptom Severity Scale, compared to placebo, and this included symptoms like abdominal pain and bloating, bowel habits, and quality of life.

“Both probiotic strains helped improve total symptomology as per the validated questionnaire, with changes that could be classified as clinically significant,” ​wrote Christopher Martoni and Gregory Leyer from UAS Labs (USA) and Shalini Srivastava from Vedic Lifesciences (India).

DDS-1 science

Commenting on the study, Dr Leyer stated: “While the research supporting our DDS-1 strain of ​L. acidophilus is copious, this clinical trial provided the opportunity to continue growing its portfolio. We have promised our partners that our foundation is built on science, and this study upholds our commitment”.

“Adding ​B. lactis as a separate arm allowed us to evaluate two different probiotic genera for optimal performance. We are beyond thrilled with the impact both have shown on digestive health,”​ he added.

Study details

The randomized, double-blind, placebo-controlled, multi-center study included 330 adults at 12 sites throughout India. All the participants had IBS according to Rome IV criteria. Volunteers were randomly assigned to one of three groups: placebo, Lactobacillus acidophilus​ DDS-1 (10 billion CFU/day), or Bifidobacterium animalis​ subsp. lactis​ UABla-12 (10 billion CFU/day) for six weeks.

Results showed that Abdominal Pain Severity - Numeric Rating Scale (APS-NRS), which was the primary outcome, significantly improved in both probiotic groups, compared to placebo.

The scientists also reported significant amelioration in IBS Symptom Severity Scale (IBS-SSS) scores for bot probiotics, compared to placebo.

In addition, participants in both probiotic groups experienced a “significant normalization in stool consistency”,​ compared to placebo.

“FDA guidance defines a responder as a decrease in weekly average abdominal pain of at least 30% compared to baseline,” ​wrote Martoni, Srivastava, and Leyer. “Clinically significant responders in the current study, considering the entire ITT population including dropouts, were 52.3% and 28.2% in the L. acidophilus DDS-1 and B. lactis UABla-12 groups respectively, both of which were significantly higher than placebo (15.6%).

“It is of interest that both probiotic strains, most notably L. acidophilus DDS-1, showed a significant group response as well an individual response to intervention.

“The high responder rates observed herein may also be applicable more generally. Episodes of abdominal pain occur in healthy people as well as individuals with IBS with the difference being the frequency and severity of symptoms. Therefore, according to the European Food Safety Authority, IBS patients are generally an appropriate study group to substantiate claims related to gastrointestinal discomfort in the general population.”

Source: Nutrients
12​(2), 363; doi: 10.3390/nu12020363
​Lactobacillus acidophilus DDS-1 and ​Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial”
Authors: C.J. Martoni et al.

Related news

Show more

Related products

show more

The Use of Alginates in Anti-Reflux Suspensions

The Use of Alginates in Anti-Reflux Suspensions

JRS PHARMA | 30-Aug-2022 | Technical / White Paper

Reflux of gastric acid into the esophagus may lead to heartburn and - in chronic cases - to gastro-esophageal reflux disease. The symptoms of heartburn...




Bionap has been named as one of the finalist with Morosil™ as “ingredient of the year” for Nutra Ingredients Usa Award 2022 in the category weight management....

Innovative colic solutions

Innovative colic solutions

Recorded the 07-Jul-2022 | Webinar

Colic is one of the most frequent reasons for visits to the pediatrician and can often lead to parental and infant exhaustion. As a functional gastrointestinal...

Register for free

Related suppliers

Follow us


View more